Literature DB >> 1727504

Inhibition of human immunodeficiency virus type 1 Rev-Rev-response element complex formation by complementary oligonucleotides.

D J Chin1.   

Abstract

Complementary 18-mer oligodeoxynucleotides (oligonucleotides) specifically inhibited the formation of human immunodeficiency virus Rev-Rev-response element (RRE) complexes. Inhibition of Rev-RRE binding required blockage of G-7819 to G-7820 in band shift assays. Structural studies revealed both local and distal effects. RRE structure was also disrupted by oligonucleotides targeted to other minor stems, by altering RNA renaturation conditions, or by reducing Rev concentrations--indicating a dynamic RRE structure and involvement of a minor RRE stem in the maturation of initial Rev-RRE complexes. Thus, complementary oligonucleotides alter RRE structure and may prove useful for the design of therapeutic anti-RRE oligonucleotides.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1727504      PMCID: PMC238324     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  43 in total

1.  The trans-activator gene of the human T cell lymphotropic virus type III is required for replication.

Authors:  A I Dayton; J G Sodroski; C A Rosen; W C Goh; W A Haseltine
Journal:  Cell       Date:  1986-03-28       Impact factor: 41.582

2.  Sequence-specific RNA binding by the HIV-1 Rev protein.

Authors:  M L Zapp; M R Green
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

Review 3.  Regulatory pathways governing HIV-1 replication.

Authors:  B R Cullen; W C Greene
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

Review 4.  Oligonucleotide analogues as potential chemotherapeutic agents.

Authors:  G Zon
Journal:  Pharm Res       Date:  1988-09       Impact factor: 4.200

Review 5.  On finding all suboptimal foldings of an RNA molecule.

Authors:  M Zuker
Journal:  Science       Date:  1989-04-07       Impact factor: 47.728

6.  Specific synthesis of DNA in vitro via a polymerase-catalyzed chain reaction.

Authors:  K B Mullis; F A Faloona
Journal:  Methods Enzymol       Date:  1987       Impact factor: 1.600

7.  Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus.

Authors:  C A Rosen; E Terwilliger; A Dayton; J G Sodroski; W A Haseltine
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

8.  Regulation of viral expression of human immunodeficiency virus in vitro by an antisense phosphorothioate oligodeoxynucleotide against rev (art/trs) in chronically infected cells.

Authors:  M Matsukura; G Zon; K Shinozuka; M Robert-Guroff; T Shimada; C A Stein; H Mitsuya; F Wong-Staal; J S Cohen; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

9.  Temperature dependent chemical and enzymatic probing of the tRNA-like structure of TYMV RNA.

Authors:  A van Belkum; P Verlaan; J B Kun; C Pleij; L Bosch
Journal:  Nucleic Acids Res       Date:  1988-03-25       Impact factor: 16.971

10.  Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro.

Authors:  T J Daly; K S Cook; G S Gray; T E Maione; J R Rusche
Journal:  Nature       Date:  1989-12-14       Impact factor: 49.962

View more
  6 in total

1.  Single-nucleotide changes in the HIV Rev-response element mediate resistance to compounds that inhibit Rev function.

Authors:  Deidra Shuck-Lee; Hua Chang; Emily A Sloan; Marie-Louise Hammarskjold; David Rekosh
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

2.  Measuring cooperative Rev protein-protein interactions on Rev responsive RNA by fluorescence resonance energy transfer.

Authors:  Thomas Vercruysse; Sonalika Pawar; Wim De Borggraeve; Els Pardon; George N Pavlakis; Christophe Pannecouque; Jan Steyaert; Jan Balzarini; Dirk Daelemans
Journal:  RNA Biol       Date:  2011-03-01       Impact factor: 4.652

3.  Inhibition of Rev activity and human immunodeficiency virus type 1 replication by antisense oligodeoxynucleotide phosphorothioate analogs directed against the Rev-responsive element.

Authors:  G Li; J Lisziewicz; D Sun; G Zon; S Daefler; F Wong-Staal; R C Gallo; M E Klotman
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

4.  Selection and characterization of human immunodeficiency virus type 1 mutants that are resistant to inhibition by the transdominant negative RevM10 protein.

Authors:  T E Hamm; D Rekosh; M L Hammarskjöld
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

5.  Specific inhibition of human immunodeficiency virus type 1 replication by antisense oligonucleotides: an in vitro model for treatment.

Authors:  J Lisziewicz; D Sun; M Klotman; S Agrawal; P Zamecnik; R Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-01       Impact factor: 11.205

6.  Human immunodeficiency virus type 1 Rev-responsive element RNA binds to host cell-specific proteins.

Authors:  R R Shukla; P L Kimmel; A Kumar
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.